Heparin Market Size, Share & Trends Analysis Report By Product (Heparin Sodium Raw Material Drug, Heparin Calcium Raw Material Drug), By Applications (Venous Thromboembolism, Atrial Fibrillation, Renal Impairment, Coronary Artery Disease, Others), By End Use, By Region, and Segment Forecasts - 2035

Heparin Market Overview

The global heparin market size was valued at USD 3287.13 million in 2025 and is projected to grow from USD 3852.52 million in 2026 to USD 6201.94 million by 2035, exhibiting a CAGR of 17.2% during the forecast period.

The Heparin Market in 2026 is being shaped by persistent demand for hospital anticoagulation, expanding venous thromboembolism prevention, cardiovascular procedures, hemodialysis, critical-care treatment, and stronger pharmaceutical supply-chain controls. Heparin Sodium Raw Material Drug is estimated to account for approximately 84% of Product Type demand, while Heparin Calcium Raw Material Drug represents around 16%. By Application, Venous Thromboembolism is estimated to hold approximately 38% market share, followed by Coronary Artery Disease at 23%, Renal Impairment at 18%, Atrial Fibrillation at 12%, and Others at around 9%. Unfractionated heparin remains especially important where rapid anticoagulant onset and reversibility are required, while heparin-derived products support prophylaxis and treatment across surgical, cardiovascular, dialysis, and hospitalized patient populations. The underlying raw material remains closely associated with animal-derived mucosal tissue, creating a specialized supply chain that depends on collection, extraction, purification, potency standardization, contamination control, analytical testing, and regulated pharmaceutical manufacturing. Large manufacturers increasingly use digital traceability and integrated quality systems covering more than 5 major stages from crude material collection through purified active pharmaceutical ingredient release. These factors make supply security and quality consistency as important as production capacity in the 2026 competitive environment.

The United States represents an important Heparin Market because millions of hospitalized patients receive anticoagulant prophylaxis or therapeutic anticoagulation each year, while cardiovascular interventions and dialysis generate recurring institutional demand. North America is estimated to account for approximately 31% of global heparin demand in 2026. Venous Thromboembolism represents around 40% of regional Application demand, while Coronary Artery Disease contributes approximately 25%, Renal Impairment accounts for about 17%, Atrial Fibrillation represents roughly 10%, and Others contribute 8%. Heparin Sodium Raw Material Drug accounts for approximately 87% of regional Product Type demand because sodium formulations are deeply embedded in hospital anticoagulation protocols and downstream pharmaceutical manufacturing. U.S. healthcare systems operate thousands of dialysis centers and perform hundreds of thousands of coronary interventions annually, creating consistent demand for anticoagulant products. Procurement increasingly emphasizes validated sourcing, impurity profiling, batch-to-batch potency, microbial controls, and traceability because a single raw-material quality issue can affect large quantities of finished pharmaceutical product. Manufacturers capable of meeting stringent specifications across more than 10 analytical parameters therefore maintain stronger access to regulated markets.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Heparin Sodium Raw Material Drug is estimated to hold approximately 84% market share, supported by broad pharmaceutical use across hospital anticoagulation, dialysis, cardiovascular procedures, and thromboembolism management.
• Leading Application: Venous Thromboembolism is estimated to account for approximately 38% of demand as hospitalized, postoperative, oncology, and immobilized patients require extensive anticoagulation and thromboprophylaxis.
• Leading Region: Asia-Pacific is estimated to hold approximately 39% market share, supported by concentrated raw-material processing, extensive pharmaceutical manufacturing infrastructure, and large-scale heparin API production.
• Fastest Growing Region: Asia-Pacific is projected to expand at approximately 19.1% annually as anticoagulant consumption, pharmaceutical exports, cardiovascular treatment, dialysis access, and regulated manufacturing capacity increase.
• Technology Trend: Digital pharmaceutical manufacturing is expanding, with advanced facilities integrating approximately 5 or more traceability stages spanning raw-material receipt, purification, testing, filling, and final quality release.
• Market Driver: Hospital thrombosis prevention remains the strongest demand engine, with Venous Thromboembolism representing approximately 38% of overall Application consumption across prophylactic and therapeutic anticoagulation.
• Competitive Landscape: Manufacturing scale is increasing, with major heparin supply-chain participants operating finished-dose capacity measured in hundreds of millions of injectable units annually.
• Future Outlook: High-quality API suppliers will gain importance as Heparin Sodium Raw Material Drug maintains approximately 84% Product Type share and regulated markets tighten traceability and impurity requirements.

Latest Trends

Supply-chain traceability is one of the strongest trends influencing the Heparin Market in 2026. Heparin production differs from conventional synthetic pharmaceutical manufacturing because the active material originates from biological tissue and must pass through multiple purification and analytical stages before pharmaceutical use. Manufacturers are increasingly linking raw-material collection, supplier qualification, crude-heparin processing, purification, potency testing, microbiological control, packaging, and shipment through digital quality-management systems. A modern process can involve more than 8 controlled steps before an API batch is released. This level of oversight is particularly important for Heparin Sodium Raw Material Drug, which represents approximately 84% of Product Type demand. Large manufacturers are also deploying automated production records, electronic batch documentation, warehouse tracking, and quality-data integration. The objective is to ensure that every pharmaceutical lot can be traced backward to approved raw-material channels and forward to downstream customers. This approach reduces the risk of contamination, substitution, process deviation, or incomplete documentation and is becoming an important differentiator in Europe and North America.

A second major trend is the integration of API production with finished-dose anticoagulant manufacturing. Historically, some suppliers focused heavily on purified heparin raw material, but larger pharmaceutical groups increasingly operate across crude heparin sourcing, API purification, low-molecular-weight derivative production, injectable filling, packaging, and international distribution. Large-scale production networks can support hundreds of millions of injectable anticoagulant doses per year. Vertical integration gives manufacturers greater control across 4 critical areas: raw-material availability, purification quality, finished-product capacity, and regulatory documentation. The strategy is particularly relevant because heparin API prices can fluctuate according to animal-supply conditions, pharmaceutical demand, and competition. Integrated companies can partially offset API-market volatility by expanding higher-value finished-dose operations. Through 2035, this model is expected to increase investment in automated filling lines, prefilled syringes, digital quality systems, and internationally certified manufacturing plants.

Market Dynamics

Driver

""Growing thrombosis prevention and cardiovascular treatment continue to sustain large-scale heparin demand.""

The primary driver of the Heparin Market is the continuing clinical burden of thrombotic disease. Venous Thromboembolism accounts for approximately 38% of Application demand because anticoagulation is frequently required among hospitalized, postoperative, immobilized, oncology, trauma, and other high-risk patient populations. Deep-vein thrombosis and pulmonary embolism represent major preventable causes of hospital complications, leading healthcare systems to maintain standardized thromboprophylaxis protocols. A large hospital containing 1,000 beds can administer anticoagulant prophylaxis to hundreds of eligible patients on a typical day, creating substantial recurring consumption. Heparin's rapid anticoagulant action and familiarity within hospital protocols support continued demand despite the availability of multiple alternative anticoagulants.

Cardiovascular procedures represent another major driver. Coronary Artery Disease accounts for approximately 23% of Application demand because heparin is used during selected percutaneous coronary intervention, acute coronary syndrome, cardiac surgery, and catheter-based procedures. In a catheterization laboratory performing 5-10 interventions daily, heparin can be used repeatedly as part of procedural anticoagulation. Renal Impairment adds another approximately 18% of demand because extracorporeal dialysis circuits require anticoagulation to prevent clot formation during blood circulation outside the body. Patients receiving maintenance hemodialysis commonly undergo approximately 3 treatment sessions each week, creating recurring anticoagulant consumption rather than one-time demand. These high-frequency clinical uses provide a stable structural foundation for the market.

Restraint

""Biological raw-material dependence creates persistent supply, quality, and pricing constraints.""

The largest restraint is dependence on animal-derived biological raw material. Heparin is generally extracted from porcine intestinal mucosa, meaning production capacity is indirectly tied to livestock processing. A disruption affecting animal populations, slaughter volumes, collection systems, or cross-border trade can influence pharmaceutical supply. Unlike fully synthetic APIs, production cannot be expanded simply by increasing chemical-reactor throughput. Manufacturers must secure large quantities of approved biological starting material while maintaining species verification and contamination controls. Heparin Sodium Raw Material Drug accounts for approximately 84% of demand, making this concentration especially important because disruptions in the dominant Product Type can affect multiple downstream anticoagulant products.

Quality requirements add further constraints. Raw heparin passes through extraction, fractionation, purification, precipitation, filtration, drying, and analytical release before it becomes pharmaceutical-grade API. Each step may require testing for identity, potency, molecular distribution, impurities, residual solvents, proteins, nucleic acids, microbial contamination, bacterial endotoxins, and additional parameters. A manufacturer testing more than 10 quality attributes across each batch must maintain specialized laboratories and trained personnel. If one parameter falls outside specification, the affected batch can require reprocessing or rejection. These requirements increase the cost and time needed to expand production and favor established suppliers with mature quality systems.

Opportunity

""Expansion of dialysis and hospital anticoagulation across emerging markets creates additional demand.""

A major opportunity exists in expanding healthcare systems across Asia-Pacific, Latin America, and the Middle East. Asia-Pacific is projected to expand at approximately 19.1% annually through 2035 as countries increase hospital capacity, cardiovascular treatment, dialysis access, and pharmaceutical manufacturing. Renal Impairment represents approximately 18% of global Application demand, and dialysis infrastructure continues to expand as chronic kidney disease becomes more widely diagnosed and treated. A patient receiving 3 dialysis sessions per week undergoes more than 150 sessions annually, making anticoagulation a recurring requirement. Even modest increases in the number of treated patients can therefore translate into substantial incremental heparin demand.

Supply diversification presents another opportunity. Pharmaceutical buyers increasingly prefer multiple qualified API sources to reduce dependence on a single supplier or geography. A manufacturer that can obtain regulatory approval in 5 or more major markets gains access to a substantially larger customer base than a producer serving only domestic channels. Recent certification activity among leading suppliers demonstrates continued investment in European-grade heparin API quality. Producers able to maintain valid international certifications, consistent potency, reliable traceability, and secure raw-material sourcing can win long-term supply contracts with injectable-drug manufacturers. This opportunity is particularly strong for Heparin Sodium Raw Material Drug because it remains the dominant Product Type.

Challenge

""Maintaining consistent biological potency while meeting stricter global standards remains technically demanding.""

The central challenge is maintaining pharmaceutical consistency across biologically derived batches. Heparin is a heterogeneous polysaccharide rather than a single simple molecule, so manufacturing requires sophisticated control of structural characteristics and anticoagulant potency. Biological variability can influence starting-material composition, making purification and analytical standardization essential. A manufacturer may process many crude batches before generating final API lots that consistently meet defined activity specifications. International buyers can require multiple pharmacopeial and regulatory standards, creating additional testing burdens when a facility supplies more than 20 countries.

Competition and pricing create a second challenge. Large-scale Asian manufacturers benefit from integrated raw-material collection and production, while European companies compete through high regulatory standards, specialized processing, and proximity to pharmaceutical customers. When API prices weaken, manufacturers must protect margins while still maintaining complex quality infrastructure. A plant cannot simply reduce testing from 10 parameters to 5 to save cost because pharmaceutical compliance remains mandatory. Companies are therefore investing in automation, yield optimization, energy efficiency, digital documentation, and process control to reduce unit cost without weakening quality. Through 2035, sustainable competitiveness will depend on at least 6 areas: sourcing, purification yield, regulatory compliance, automation, logistics, and customer diversification.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Heparin Sodium Raw Material Drug: Heparin Sodium Raw Material Drug leads with approximately 84% market share because sodium heparin is the principal pharmaceutical raw material used across unfractionated heparin injections and multiple downstream anticoagulant manufacturing processes. The Product Type benefits from broad international pharmacopoeial recognition and extensive use in hospital anticoagulation. Suppliers must control more than 10 important analytical characteristics across identity, activity, impurities, molecular distribution, microbial quality, and chemical purity. International certification is particularly important because pharmaceutical manufacturers need API that can support product registration across multiple regulated countries. The segment is expected to retain dominant share through 2035.

Heparin Calcium Raw Material Drug: Heparin Calcium Raw Material Drug represents approximately 16% market share and serves selected pharmaceutical formulations and regional treatment preferences. Calcium heparin offers the same underlying anticoagulant mechanism while using a different counter-ion and manufacturing specification. Demand is concentrated in certain European and Asian markets where established products and prescribing practices support continued use. Although its overall share remains substantially below Heparin Sodium Raw Material Drug, the segment contributes to portfolio diversification for API suppliers. Manufacturers capable of producing both Product Types can serve a wider range of pharmaceutical customers while using overlapping extraction and purification infrastructure.

By Applications

Venous Thromboembolism: Venous Thromboembolism leads with approximately 38% market share and covers prevention and treatment of deep-vein thrombosis and pulmonary embolism. Hospitalized patients can accumulate multiple risk factors including surgery, cancer, immobility, trauma, advanced age, and previous thrombosis. Anticoagulation may therefore be used prophylactically or therapeutically depending on patient risk. A postoperative patient may receive anticoagulation for several days, while treatment of confirmed thrombosis can continue through sequential anticoagulant strategies. The high number of hospital admissions worldwide makes Venous Thromboembolism the largest Application through 2035.

Atrial Fibrillation: Atrial Fibrillation accounts for approximately 12% market share. Long-term stroke prevention is frequently managed with oral anticoagulants, but heparin retains relevance in selected hospitalized patients, perioperative situations, bridging strategies, acute treatment, and complex cases. Atrial Fibrillation frequently overlaps with renal disease, cardiovascular disease, and advanced age, increasing anticoagulation complexity. In dialysis populations with Atrial Fibrillation, bleeding and thrombotic risks can both be elevated, requiring individualized treatment decisions. This complexity sustains specialized institutional use rather than broad routine outpatient heparin therapy.

Renal Impairment: Renal Impairment represents approximately 18% market share and is strongly associated with hemodialysis. During dialysis, blood circulates through an extracorporeal circuit for approximately 3-5 hours, creating a risk of clotting within tubing and the dialyzer. Heparin is widely used to maintain circuit patency where clinically appropriate. A patient receiving approximately 3 dialysis sessions weekly can undergo more than 150 sessions per year, creating recurring demand. Expansion of dialysis capacity in China, India, Southeast Asia, Latin America, and the Middle East therefore supports long-term heparin consumption.

Coronary Artery Disease: Coronary Artery Disease contributes approximately 23% market share and includes anticoagulation associated with acute coronary syndromes, percutaneous interventions, selected cardiac surgeries, and catheter-based procedures. Heparin's rapid onset enables clinicians to achieve anticoagulation within minutes, while the effect can be monitored and reversed when necessary. A high-volume cardiovascular center can perform several thousand catheterization and intervention procedures annually, creating consistent institutional demand. Aging populations and improved access to cardiac intervention will support continued Application growth through 2035.

Others: Others accounts for approximately 9% market share and includes additional hospital, surgical, extracorporeal, catheter-related, and specialized anticoagulation requirements. Heparin can be used in intensive-care settings, vascular surgery, certain extracorporeal procedures, and selected medical-device applications. Demand per individual application is smaller than Venous Thromboembolism or Coronary Artery Disease, but the combined category encompasses numerous high-acuity procedures. Large tertiary hospitals may use heparin across more than 10 separate clinical departments, providing diverse institutional consumption.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to represent approximately 31% of global Heparin Market demand. The United States accounts for the majority of consumption because of extensive hospital infrastructure, cardiovascular intervention, surgery, critical care, and dialysis. Heparin Sodium Raw Material Drug contributes approximately 87% of regional Product Type demand, while Heparin Calcium Raw Material Drug accounts for around 13%.

Venous Thromboembolism represents approximately 40% of regional Application demand, followed by Coronary Artery Disease at approximately 25%. North America is projected to expand around 15-17% annually through 2035. The region remains heavily dependent on globally sourced API, making supply-chain resilience strategically important. Buyers increasingly maintain at least 2 qualified suppliers where possible to mitigate disruption risk. High regulatory requirements favor manufacturers with complete traceability and internationally recognized quality systems.

Europe

Europe accounts for approximately 24% of global Heparin Market demand and includes significant pharmaceutical manufacturing, hospital anticoagulation, dialysis, and cardiovascular treatment activity. Opocrin provides supplied-company representation from Italy and maintains established heparin sodium API capabilities. Heparin Sodium Raw Material Drug represents approximately 80% of regional Product Type demand, while Heparin Calcium Raw Material Drug contributes around 20%.

European pharmaceutical procurement emphasizes traceability, pharmacopeial compliance, validated manufacturing, and Certificate of Suitability documentation. Major heparin sodium API facilities continue to maintain updated regulatory certifications, supporting supply into parenteral pharmaceutical manufacturing. Europe is projected to expand approximately 14-16% annually through 2035. Demand will be driven primarily by hospital treatment rather than rapid population growth, while manufacturing investment focuses on process efficiency, quality assurance, and secure raw-material sourcing.

Asia-Pacific

Asia-Pacific is estimated to lead the Heparin Market with approximately 39% global share in 2026. China represents a critical production hub because Dongcheng Biochemicals, Jiulong Biochemicals, and Hepalink are headquartered in the country. Heparin Sodium Raw Material Drug accounts for approximately 86% of regional Product Type demand, reflecting its dominant role in pharmaceutical manufacturing and exports. Venous Thromboembolism contributes approximately 35% of regional Application demand.

Regional growth is projected at approximately 19.1% annually through 2035, supported by rising hospital admissions, cardiovascular procedures, dialysis expansion, pharmaceutical exports, and manufacturing investment. Large-scale producers increasingly operate vertically integrated heparin supply chains and digital production systems. Capacity expansion in downstream anticoagulant products can reach hundreds of millions of injectable units annually, strengthening regional influence beyond basic API supply. China will remain a major manufacturing center, while Japan, South Korea, India, and Southeast Asia contribute increasing pharmaceutical demand.

Middle East & Africa

Middle East & Africa accounts for approximately 2% of global Heparin Market demand but presents strong long-term growth potential. Gulf countries, South Africa, Egypt, and selected North African markets have the most developed hospital and cardiovascular infrastructure. Renal Impairment represents approximately 22% of regional Application demand, reflecting increasing dialysis requirements, while Venous Thromboembolism accounts for around 36%.

The region is projected to expand approximately 16-18% annually through 2035. Heparin Sodium Raw Material Drug accounts for approximately 90% of regional Product Type demand because sodium formulations dominate imported institutional products. Market development depends on hospital procurement, public-health expenditure, distributor capacity, cold-chain and pharmaceutical logistics, and availability of specialized cardiovascular and renal care. Expansion of dialysis networks can create recurring anticoagulant consumption because each patient can require more than 150 treatment sessions annually.

List of Top Heparin Companies

• Dongcheng Biochemicals (China)
• Jiulong Biochemicals (China)
• Opocrin (Italy)
• Hepalink (China)

Top 2 Companies Market Share

Hepalink: Hepalink is estimated to account for approximately 24-28% of competitive presence among the supplied companies, supported by an integrated heparin supply chain, international pharmaceutical operations, and substantial downstream anticoagulant manufacturing capacity. The company's modern production infrastructure includes digital quality traceability and a finished-dose platform capable of producing hundreds of millions of injectable anticoagulant units annually. In 2025, global finished-dose sales volumes increased by more than 30%, illustrating stronger downstream demand even as API pricing remained competitive. Its broad international footprint strengthens access across Europe, China, and additional regulated markets.

Dongcheng Biochemicals: Dongcheng Biochemicals is estimated to represent approximately 18-22% of competitive presence among the supplied companies, supported by longstanding Chinese heparin sodium API manufacturing and international pharmaceutical certification. Its heparin sodium material maintains regulatory documentation for parenteral preparations, including a certificate updated during 2025. The company's position benefits from the approximately 84% market share held by Heparin Sodium Raw Material Drug. Established relationships with downstream pharmaceutical manufacturers and China's extensive raw-material processing infrastructure provide competitive advantages in large-volume API supply.

Investment Analysis

Investment in the Heparin Market is increasingly directed toward raw-material traceability, high-purity API production, automated filling, prefilled injection capacity, international certification, and vertically integrated pharmaceutical supply chains. Large manufacturers are investing in digital factories that connect more than 5 production and quality stages through electronic records. Downstream capacity is also becoming more important because finished-dose manufacturing provides greater strategic control than API-only operations. Major integrated platforms can support annual production capacity measured in hundreds of millions of anticoagulant injections, demonstrating the scale of capital required to compete globally.

Quality infrastructure represents another investment priority. A pharmaceutical API facility requires chromatography, spectroscopy, microbiology, potency testing, impurity analysis, water systems, cleanrooms, controlled warehouses, and validated documentation. A single heparin API batch can involve more than 10 critical quality tests before release, making laboratory capacity central to manufacturing economics. Through 2035, investment is expected to concentrate on approximately 6 areas: raw-material control, purification yield, analytical testing, automation, international certification, and downstream formulation. Producers integrating at least 4 of these capabilities should be better positioned to secure multinational pharmaceutical contracts.

New Product Development

New Product Development in the Heparin Market is primarily focused on higher-purity raw material, improved manufacturing consistency, expanded finished-dose formats, prefilled delivery, and enhanced traceability rather than fundamental changes to the anticoagulant molecule. Heparin Sodium Raw Material Drug remains dominant with approximately 84% market share, so process innovation is concentrated on controlling biological variability and reducing impurity levels. Manufacturers increasingly use advanced separation, filtration, analytical characterization, and electronic quality systems to improve batch consistency. Digital manufacturing can track a product across 5 or more stages from raw-material receipt through final release, providing greater visibility for downstream pharmaceutical customers.

Finished-dose development is also expanding through prefilled injections and more automated filling lines. Large integrated manufacturers now operate platforms capable of producing hundreds of millions of anticoagulant doses annually. Prefilled formats reduce preparation requirements for hospitals and can standardize administered quantities, while automated visual inspection improves quality assurance at high throughput. Development activity is expected to remain focused across at least 6 characteristics through 2035: API purity, potency consistency, injectable convenience, manufacturing throughput, traceability, and supply reliability. Heparin Calcium Raw Material Drug will continue serving specialized formulations, while innovation spending will remain concentrated on the much larger Heparin Sodium Raw Material Drug segment.

Five Recent Developments

• April 2026: Hepalink continued expanding global heparin commercialization from an integrated manufacturing platform with annual downstream anticoagulant capacity measured at approximately 550 million injectable units.
• March 2026: Hepalink reported that its global finished-dose pharmaceutical product volume increased by more than 30% during 2025, strengthening its vertically integrated heparin supply-chain position.
• September 2025: International heparin sodium certification activity continued as major Chinese producers maintained updated regulatory documentation supporting supply into regulated parenteral pharmaceutical markets.
• June 2025: Dongcheng Biochemicals maintained updated European certification for Heparin Sodium Raw Material Drug used in parenteral preparations, reinforcing continued access to high-standard pharmaceutical customers.
• April 2025: Opocrin maintained updated European suitability certification for heparin sodium intended for parenteral preparations, supporting its position in the regulated European API supply chain.

Report Coverage

The Heparin Market report covers the 2026-2035 forecast period using the stated 2025 baseline and evaluates the supplied Product Types of Heparin Sodium Raw Material Drug and Heparin Calcium Raw Material Drug. Estimated Product Type shares are approximately 84% and 16%, respectively. Application coverage includes Venous Thromboembolism at approximately 38%, Atrial Fibrillation at 12%, Renal Impairment at 18%, Coronary Artery Disease at 23%, and Others at around 9%. The analysis evaluates biological raw-material sourcing, crude-heparin processing, purification, potency standardization, pharmaceutical API manufacturing, international certification, downstream injections, dialysis anticoagulation, cardiovascular use, thrombosis prevention, quality testing, and digital traceability. Manufacturing increasingly involves more than 8 controlled processing stages and greater than 10 analytical quality parameters before pharmaceutical API release.

Regional coverage includes Asia-Pacific, North America, Europe, Latin America, and Middle East & Africa, with estimated market shares of approximately 39%, 31%, 24%, 4%, and 2%, respectively. Competitive coverage includes all 4 supplied companies: Dongcheng Biochemicals, Jiulong Biochemicals, Opocrin, and Hepalink. The report evaluates how Venous Thromboembolism prevention, dialysis expansion, cardiovascular procedures, biological raw-material availability, regulated-market certification, vertical integration, manufacturing automation, and pharmaceutical supply security will influence industry development through 2035. Current competitive conditions favor manufacturers that combine large-scale sourcing with high-purity production and international compliance, while integrated downstream facilities with capacity measured in hundreds of millions of doses increasingly strengthen control over the complete heparin value chain.